Article content continued

Supreme Pharmaceuticals in the last 30 days has seen its share price increase from $1.18 on Oct. 19 to $1.90 on Nov. 18 — an increase of over 60 per cent on volume of just under 71 million shares. And that’s on the Canadian Securities Exchange, making it a record-breaking stock on so many levels it would take a small textbook to enumerate them all.

Aphria Inc. is in a similar situation, but its valuation has increased even more dramatically. On Oct.19, Aphria closed at $3.82. At midday on Friday, Aphria’s share price was $6.78. In the last 30 days, it has traded a total of 70.1 million shares, just under Supreme’s volumes, and it’s up by 77 per cent.

Organigram Holdings too has seen a dramatic uptick in volume and price. Its price is up only 26 per cent in the last month, though its volumes are similarly high at just under 80 million for the month at $3.84 as of midday Friday.

But the granddaddy of them all, as has been the case since day one of the marijuana industry’s birth, is Canopy Growth Corp., formerly Tweed Marijuana (now a subsidiary of Canopy). A month ago it closed at $7.06 a share, which represented a double at that time from its close a month prior to that. But in the last 30 days, its stock has traded as high as $17.86, an increase of 152.62 per cent. It has since backed off to $12.49, as those are the kinds of volumes that attract short sellers and algorithmic high speed frequency traders.

That’s the kind of win most investors only dream about.

James West is an investor and the author of the Midas Letter, an investing research report focused on Canadian markets. The views expressed are his own and are presented for general informational purposes only. They should not be construed as advice to invest in any securities mentioned.

James West and/or associated funds do not own shares in any securities mentioned in this article. For the full Midas Letter disclosure policy, click here. Postmedia and Midas Letter have a revenue sharing arrangement.